Alfred Morgenstern

Karlsruhe, BW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 157 publications

Prognostic value of circulating tumor DNA and copy-number alterations in patients receiving tandem [225Ac]Ac-/[177Lu]Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer: a prospective observational study.

Prognostic value of circulating tumor DNA and copy-number alterations in patients receiving tandem [225Ac]Ac-/[177Lu]Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer: a prospective observational study.

Journal: BMC cancer
Published: May 17, 2026

Actinium-225-rhPSMA-10.1 as a novel, alpha-particle-emitting therapy for prostate cancer: results of a preclinical evaluation.

Actinium-225-rhPSMA-10.1 as a novel, alpha-particle-emitting therapy for prostate cancer: results of a preclinical evaluation.

Journal: Frontiers in oncology
Published: April 29, 2026

Predicting tumour and organ dose in α-radiopharmaceutical therapy: a 89Zr-based dosimetric approach for 225Ac.

Predicting tumour and organ dose in α-radiopharmaceutical therapy: a 89Zr-based dosimetric approach for 225Ac.

Journal: European journal of nuclear medicine and molecular imaging
Published: April 02, 2026

Inline gamma spectroscopy and liquid scintillation HPLC reveal daughters in 225Ac-radiopharmaceutical.

Inline gamma spectroscopy and liquid scintillation HPLC reveal daughters in 225Ac-radiopharmaceutical.

Journal: EJNMMI radiopharmacy and chemistry
Published: March 10, 2026

Chelator-Free Radiometal Labeling Inside Engineered Affibodies.

Chelator-Free Radiometal Labeling Inside Engineered Affibodies.

Journal: Angewandte Chemie (International ed. in English)
Published: January 28, 2026

Phase 1 Dose-Escalation Study of [225Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry.

Phase 1 Dose-Escalation Study of [225Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: December 16, 2025

EpCAM-PSMA: Potential predictors of treatment outcomes for PSMA-targeted alpha therapies in metastatic castration-resistant prostate cancer.

EpCAM-PSMA: Potential predictors of treatment outcomes for PSMA-targeted alpha therapies in metastatic castration-resistant prostate cancer.

Journal: Molecular therapy. Oncology
Published: November 18, 2025

Genomic analysis in chemotherapy-naïve prostate cancer prior to PSMA-targeted treatment.

Genomic analysis in chemotherapy-naïve prostate cancer prior to PSMA-targeted treatment.

Journal: Frontiers in oncology
Published: November 06, 2025

Exploratory case series of circulating tumor DNA dynamics during tandem therapy in metastatic castration-resistant prostate cancer.

Exploratory case series of circulating tumor DNA dynamics during tandem therapy in metastatic castration-resistant prostate cancer.

Journal: EJNMMI research
Published: October 02, 2025

Convection-enhanced delivery of [225Ac]Ac-DOTA-SP in recurrent glioblastoma - tumour uptake.

Convection-enhanced delivery of [225Ac]Ac-DOTA-SP in recurrent glioblastoma - tumour uptake.

Journal: European journal of nuclear medicine and molecular imaging
Published: July 21, 2025

[225Ac]Ac-PSMA I&T: A Preclinical Investigation on the Fate of Decay Nuclides and Their Influence on Dosimetry of Salivary Glands and Kidneys.

[225Ac]Ac-PSMA I&T: A Preclinical Investigation on the Fate of Decay Nuclides and Their Influence on Dosimetry of Salivary Glands and Kidneys.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: February 18, 2025

[225Ac]Ac-PSMA I&T: A Preclinical Investigation on the Fate of Decay Nuclides and Their Influence on Dosimetry of Salivary Glands and Kidneys.

[225Ac]Ac-PSMA I&T: A Preclinical Investigation on the Fate of Decay Nuclides and Their Influence on Dosimetry of Salivary Glands and Kidneys.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: February 18, 2025
Showing 1-12 of 157

Last Updated: 09/26/2026